|Principal Investigator/ Physician||Weisi Yan, MD|
|Contact Email||MCI Clinical Trials|
Protocol: Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy For Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Inclusion Criteia: Zubrod performance status 0, 1, or 2 within 30 days prior to registration; must have received first-line/induction chemotherapy (4 cycles) and achieved stable disease or a partial response; Prior systemic chemotherapy as part of concurrent treatment approach for previously diagnosed stage III NSCLC; Prior radiotherapy for patients with brain metastases prior to enrollment is acceptable;must have measurable disease at baseline and 3 or fewer discrete, extracranial metastatic disease sites that are technically amenable to SBRT.
Exclusion Criteria: Clinical or radiologic evidence of untreated and/or progressive brain metastases; Cutaneous metastasis of NSCLC; Metastatic disease invading the esophagus, stomach, intestines, or mesenteric lymph nodes; Prior invasive malignancy unless disease free for a minimum of one year; receiving targeted therapy; progressed in previous areas of primary disease that received definitive doses of radiation; more than 3 discrete locations of extra-cranial metastatic disease after first-line systemic therapy requiring more than 3 SBRT plans to cover these distinct metastatic disease entities; Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.
Clinical Trials.Gov Link: https://clinicaltrials.gov/ct2/show/NCT03137771?term=LU002&recrs=a&rank=1
© 2018 USA Health System